Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
The first global pivotal trial will be in first-line triple-negative breast cancer.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
